Reason for request
Reassessment of medicines containing methylphenidate in attention deficit hyperactivity disorder in response to the instruction from the Directorate-General for Health.
Clinical Benefit
| Substantial |
The actual benefit of QUASYM LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years old and over when psychological, educational and social management alone prove insufficient. |
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
K9NGUBzRvA9g39eE
